Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.
The panel explores promising biomarker research that has the potential to significantly impact patient care in prostate cancer.
Prostate cancer specialists share their insights on anticipated future advancements that could significantly influence prostate cancer management strategies.
Michael Gorin, MD discusses the impact of next-day imaging and the potential imaging improvements as physicians await the results of the CLARIFY trial.
Michael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent.
"From a revenue, profit and loss perspective, actually, in many instances, they anticipate that physicians may actually make more money using the second-generation CVAC device compared to traditional ureteroscopy, depending on your payer mix and your practice," says Thomas Chi, MD, MBA.
The TiNivo-2 trial demonstrated that rechallenging ICI therapy does not improve outcomes in patients with renal cell carcinoma.
“We already have very effective ARPIs available around the world, and this will add to those therapeutic options to try to tailor patients based on their needs [and] their particular profiles,” says Fred Saad, MD, FRCS.
“I think that these data in this approximately 700 patient trial consolidates and makes a strong case for the role of pembrolizumab in the adjuvant setting,” says Guru P. Sonpavde, MD.
“Today, we're presenting the results of this analysis, and we show that patients who have a high Decipher score derive significant benefit from docetaxel,” says Gerhardt Attard, MD, PhD, FRCP.
"It clearly shows that blocking HIF-2α is a meaningful way of interacting with disease biology in clear cell renal cell carcinoma," says Eric Jonasch, MD.
“[We’re] trying to anticipate with a smartwatch some of the catastrophic blood pressure changes and things that happen in these patients,” says Matthew J. Mellon, MD, FACS.
Thomas Chi, MD, MBA, discusses advantages to the CVAC System.
Panelists discuss how to address the challenges in providing optimal care for mCRPC patients and how barriers may vary between different healthcare settings, such as rural vs. urban and private vs. public.
Panelists discuss how the dosing and administration of different abiraterone formulations vary, how food-related effects impact treatment efficacy, and strategies to manage these effects for optimal patient outcomes.
The key opinion leaders explore strategies for integrating newly available diagnostic tests into the existing treatment paradigm and patient journey.
The panel examines the significance of biomarkers in assessing therapy outcomes for prostate cancer patients, while also exploring the concept of absolute benefit in metastasis risk when adding androgen deprivation therapy (ADT) to radiation therapy for newly diagnosed cases.
"I think it's going to help younger or less experienced urologists get more proficient at this procedure faster. That's where the AI is going to come into play," says Lewis S. Kriteman, MD, FACS.
A medical expert discusses how emerging copper-based developments in PSMA imaging, particularly the 64Cu-SAR-bisPSMA agent, offer advancements in tumor detection and imaging logistics compared to traditional agents.
A medical expert discusses how advancements in PSMA PET imaging, including the development of agents like 64Cu-SAR-bisPSMA, address current challenges in sensitivity and logistical issues, potentially enhancing tumor detection and patient outcomes.
“In the period where a patient receives a diagnosis of favorable intermediate-risk cancer or higher and doesn't know what to do, there is a big unmet need/gap that we aim to serve with Unfold AI,” says Shyam Natarajan, PhD.
“I think that there will probably be much more accessible tools within the next 5 years, and almost certainly within the next 10 years,” says Yair Lotan, MD.
"It's really upon us, as the medical community, to be better about not just antibiotic stewardship, but also diagnostic stewardship," says A. Lenore Ackerman, MD, PhD.
"That's probably the biggest thing that I would say to somebody who's interested in urology is, do you think you can get on another patient's level?" says Emily Sopko, CNP.
"What we demonstrated was that at 30-day and 90-day interval outcomes, the patients actually had equivalent safety profiles compared to traditional ureteroscopy with basketing," says Thomas Chi, MD, MBA.
Dean Elterman, MD, discusses how minimally invasive surgical therapies (MIST) are increasingly integrated into the treatment landscape for benign prostatic hyperplasia (BPH), addressing unmet needs and offering new options, while also highlighting ongoing trials and investigations that aim to further refine these approaches.
Dean Elterman, MD, discusses how a comprehensive approach to diagnosing and managing benign prostatic hyperplasia (BPH) involves a combination of symptom assessment, lifestyle modifications, pharmacotherapy, and regular follow-up to optimize patient outcomes.
"We see use of AI-generated cancer maps in the decision-making process of understanding who is the right patient for what therapy, as well as planning out the specific therapy," says Shyam Natarajan, PhD.
"I like working alongside the residents, because they've taught me pretty much everything that I know about urology," says Emily Sopko, CNP.
“So, I think we have to be conscious that when we're developing these tools that we're inclusive,” says Yair Lotan, MD.
